{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:03:45Z","timestamp":1784808225775,"version":"3.55.0"},"reference-count":15,"publisher":"Jaypee Brothers Medical Publishing","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.59556\/japi.74.1524","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:55:55Z","timestamp":1781603755000},"page":"e1-e5","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Indacaterol\/Glycopyrronium\/Mometasone Dry Powder Inhaler in Asthma: A Prospective Multicenter Phase IV Study"],"prefix":"10.59556","volume":"74","author":[{"given":"Saurabh","family":"Karmakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit S","family":"Bhate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Prashanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Kadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan B","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Budhraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utpal","family":"Nandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amogh","family":"Lotankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kundan","family":"Nivangune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(10122):","key":"key20260723113214_B1","doi-asserted-by":"crossref","first-page":"783\u2013","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma.","volume":"391","author":"Papi","year":"2018;","journal-title":"Lancet"},{"issue":"(1):","key":"key20260723113214_B2","doi-asserted-by":"crossref","first-page":"e003144.","DOI":"10.1136\/bmjresp-2025-003144","article-title":"Global, regional, and national burden of asthma from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"12","author":"Zhang","year":"2025;","journal-title":"BMJ Open Respir Res"},{"issue":"(3):","key":"key20260723113214_B3","doi-asserted-by":"crossref","first-page":"209\u2013","DOI":"10.4103\/lungindia.lungindia_518_23","article-title":"Call to action: Addressing asthma diagnosis and treatment gaps in India.","volume":"41","author":"Swarnakar","year":"2024;","journal-title":"Lung India"},{"issue":"(3):","key":"key20260723113214_B4","doi-asserted-by":"crossref","first-page":"514\u2013","DOI":"10.3390\/ph3030514","article-title":"Inhaled corticosteroids.","volume":"3","author":"Barnes","year":"2010;","journal-title":"Pharmaceuticals (Basel)"},{"issue":"(1):","key":"key20260723113214_B5","first-page":"2102730.","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes.","volume":"59","author":"Reddel","year":"2021;","journal-title":"Eur Respir J"},{"key":"key20260723113214_B6","doi-asserted-by":"crossref","first-page":"101828.","DOI":"10.1016\/j.pupt.2019.101828","article-title":"Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment.","volume":"58:","author":"Matera","year":"2019;","journal-title":"Pulm Pharmacol Ther"},{"key":"key20260723113214_B7","doi-asserted-by":"crossref","first-page":"8881895.","DOI":"10.1155\/2021\/8881895","article-title":"The role of ICS\/LABA fixed-dose combinations in the treatment of asthma and COPD: bioequivalence of a generic fluticasone propionate-salmeterol device.","volume":"2021:","author":"Tashkin","year":"2021;","journal-title":"Pulm Med"},{"key":"key20260723113214_B8","doi-asserted-by":"crossref","first-page":"14\u2013","DOI":"10.1016\/j.ejim.2021.01.027","article-title":"Inhaled long-acting muscarinic antagonists in asthma - a narrative review.","volume":"85:","author":"Papi","year":"2021;","journal-title":"Eur J Intern Med"},{"issue":"(10210):","key":"key20260723113214_B9","doi-asserted-by":"crossref","first-page":"1737\u2013","DOI":"10.1016\/S0140-6736(19)32215-9","article-title":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomized, controlled phase 3 trials.","volume":"394","author":"Virchow","year":"2019;","journal-title":"Lancet"},{"key":"key20260723113214_B10","doi-asserted-by":"crossref","first-page":"107172.","DOI":"10.1016\/j.rmed.2023.107172","article-title":"Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone\/indacaterol\/glycopyrronium in patients with asthma with or without persistent airflow limitation: post hoc analysis from the IRIDIUM study.","volume":"211:","author":"Van Zyl-Smit","year":"2023;","journal-title":"Respir Med"},{"issue":"(2):","key":"key20260723113214_B11","doi-asserted-by":"crossref","first-page":"216\u2013","DOI":"10.1080\/02770903.2024.2394152","article-title":"Evaluating the timing of triple therapy initiation for the treatment of asthma in Japan: prompt versus delayed.","volume":"62","author":"Requena","year":"2025;","journal-title":"J Asthma"},{"key":"key20260723113214_B12","doi-asserted-by":"crossref","first-page":"106021.","DOI":"10.1016\/j.rmed.2020.106021","article-title":"Fixed-dose combination of indacaterol\/glycopyrronium\/mometasone furoate once-daily versus salmeterol\/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON).","volume":"170:","author":"Gessner","year":"2020;","journal-title":"Respir Med"},{"key":"key20260723113214_B13","doi-asserted-by":"crossref","first-page":"1309\u2013","DOI":"10.2147\/JAA.S424055","article-title":"Real-world study of single-inhaler triple therapy with fluticasone furoate\/umeclidinium\/vilanterol on asthma control in the US.","volume":"16:","author":"Bogart","year":"2023;","journal-title":"J Asthma Allergy"},{"issue":"(2):","key":"key20260723113214_B14","first-page":"AB266.","article-title":"Is asthma clinical remission achievable by inhaled therapy? A post-hoc analysis of single inhaler triple therapy with FF\/UMEC\/VI in the CAPTAIN trial.","volume":"153","author":"Lugogo","year":"2025;","journal-title":"J Allergy Clin Immunol"},{"key":"key20260723113214_B15","doi-asserted-by":"crossref","first-page":"685\u2013","DOI":"10.1016\/j.resinv.2024.05.011","article-title":"Real-world characteristics of patients with asthma initiating fluticasone furoate\/umeclidinium\/vilanterol single-inhaler triple therapy in Japan.","volume":"62:","author":"Oga","year":"2024;","journal-title":"Respir Investig"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:32:21Z","timestamp":1784806341000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-6-e1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.59556\/japi.74.1524"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1524","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}